<DOC>
	<DOCNO>NCT02057887</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability multiple ascending dos HM10660A subject chronic hepatitis C ( HCV ) .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetic Study Recombinant Human Interferon Alfa 2B Chronic Hepatitis C Patients ( HM10660A )</brief_title>
	<detailed_description>- To evaluate repeat-dose pharmacokinetics ( PK ) HM10660A give weekly , biweekly , monthly subcutaneous ( SC ) injection . - To evaluate repeat-dose pharmacodynamics ( PD ) HM10660A give weekly , biweekly , monthly SC injection . - To explore antiviral activity HM10660A Week 4 , Week 12 , Week 24 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Male female , age 18 65 year old , inclusive Willing able provide write informed consent . Previously untreated HCV infection HCV RNA &gt; 75,000 IU/mL screening . HCV genotype 1a 1b . Body mass index ( BMI ) 18 38 kg/m2 . Willing able comply protocol available complete study schedule assessment . Pregnant woman woman may wish become pregnant course study . Males females reproductive potential unwilling use 2 form effective birth control throughout duration study treatment least 6 month last dose RBV . One method include condom spermicide male . Males must agree refrain sperm donation least 6 month last dose RBV . Evidence infection coinfection nongenotype 1 HCV strain . Coinfection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) . Lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>